Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma

L Di Lauro, C Nunziata, M G Arena, P Foggi, I Sperduti, M Lopez, L Di Lauro, C Nunziata, M G Arena, P Foggi, I Sperduti, M Lopez

Abstract

This phase II study was designed to evaluate the activity and safety of a combination of irinotecan, docetaxel and oxaliplatin in metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Forty patients with measurable distant metastasis received irinotecan 150 mg m(-2) and docetaxel 60 mg m(-2) on day 1, and oxaliplatin 85 mg m(-2) on day 2. Cycles were repeated every 3 weeks. The primary end point was to demonstrate a 50% improvement in time-to-progression (TTP) over historical controls. All patients were evaluable. Median TTP was 6.5 months (95% confidence interval (CI) 5.6-7.4), the overall response rate was 50% (95% CI 35-65%) and the median overall survival was 11.5 months (95% CI 8.7-14.3). Grade 3/4 neutropaenia occurred in 47.5% of patients. There were four episodes of febrile neutropaenia in three patients. Other non-haematological grade 3 toxicities included diarrhoea in four patients (10%), vomiting in three patients (7.5%) and mucositis in two patients (5%). The irinotecan, docetaxel and oxaliplatin combination chemotherapy is an active and well-tolerated novel regimen for treating metastatic gastric or GEJ adenocarcinoma and deserves further evaluation in randomised trials and in combination with molecular targeting agents.

Figures

Figure 1
Figure 1
Median TTP for all patients.
Figure 2
Figure 2
Overall survival for all patients.

References

    1. A'Hern RP (2001) Sample size tables for exact single-stage phase II designs. Statist Med 20: 859–866
    1. Ajani J (2006) Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 107: 221–231
    1. Al-Batran SE, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S, Rummel MJ, Seipelt G, Rost A, Orth J, Knuth A, Jaeger E (2004) Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 22: 658–663
    1. Bleiberg H (1999) CPT-11 in gastrointestinal cancer. Eur J Cancer 35: 371–379
    1. Chang HM, Kim TW, Yook JH, Oh ST, Kim WK, Lee JS, Kang JK (2003) Phase II study of irinotecan (I) and docetaxel (D) as second line chemotherapy for patients with previously treated advanced gastric cancer (AGC). Proc Am Soc Clin Oncol 22: 328 (abstract 1316)
    1. Cunningham D, Rao S, Starling N, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR (2006) Randomized multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OC) cancer: The REAL 2 trial. J Clin Oncol 24(S18): 182s (abstract LBA4017)
    1. Dank M, Zaluski J, Barone C, Valvere V, Peschel C, Wenczl M, Goker E, Risse M, Award L, Bugatet R (2005) Randomized phase 3 trial of irinotecan (CPT-11)+ 5FU/folinic acid (FA) vs CDDP+5FU in 1st-line advanced gastric cancer patients. J Clin Oncol 23(S16): 308s (abstract 4003)
    1. Devesa SS, Fraumeni JF (1999) The rising incidence of gastric cardia cancer. J Natl Cancer Inst 91: 747–749
    1. Hawkins R, Cunningham D, Soerbye H, Adenis A, Canon JL, Lopez-Vivanco G, Jacques C, Stenger P, Zuber E, Misset JL (2003) Randomized phase II trial of docetaxel plus irinotecan vs docetaxel plus 5-fluorouracil (5FU) in patients with untreated advanced gastric adenocarcinoma (AGAC). Proc Am Soc Clin Oncol 22: 257 (abstract 1032)
    1. Hundahl S, Phillips J, Menck H (2000) The national cancer data base report on poor survival of US gastric carcinoma patients treated with gastrectomy: fifth edition American joint committee on cancer staging, proximal disease, and the ‘different disease’ hypothesis. Cancer 88: 921–932
    1. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137–2150
    1. Kohne CH, Thuss-Patience P, Catane R, Klein H, Peretz T, Preusser P, Niederle N, Ducreux M, Hansjokem W, Jacques C (1999) Final results of a phase II trial of CPT-11 in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 18: 258 (abstract 993)
    1. Louvet C, André T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, Francois E, Jacob JH, Levoir D, Taamma A, Rougier P, Cvitkovic E, de Gramont A (2002) Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20: 4543–4548
    1. Park SR, Chun JH, Yu MS, Lee JH, Ryu KW, Choi IJ, Kim CG, Lee JS, Kim YW, Bae JM, Kim HK (2006) Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma. Br J Cancer 94: 1402–1406
    1. Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, Mutri V, Giannetta L, Giaquinta S, Funaioli C, Berardi R, Longobardi C, Piana E, Martoni A (2007) Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 18: 510–517
    1. Richards DA, Wilfong L, Reznick D, McCollum D, Boehm KA, Zhan L, Asmar L (2006) Phase II multicenter trial of docetaxel+oxaliplatin in stage IV gastroesophageal and/or stomach cancer. J Clin Oncol 24(S18): 195s (abstract 4071)
    1. Rivera F, Vega-Villegas ME, Lopez-Brea MF (2007) Chemotherapy of advanced gastric cancer. Cancer Treat Rev 33: 315–324
    1. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK, Kelsen DP (2006) Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24: 5201–5206
    1. Souglakos J, Syrigos K, Potamianou A, Polyzos A, Boukovinas I, Androulakis N, Kouroussis C, Vardakis N, Christophilakis C, Kotsakis A, Georgoulias V (2004) Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial. Ann Oncol 15: 1204–1209
    1. Therasse P, Arbuck SG, Eisenhauer E, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 92: 205–216
    1. Thuss-Patience PC, Kretzschmar A, Reichardt P (2006) Docetaxel in the treatment of gastric cancer. Future Oncol 2: 603–620
    1. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 24: 4991–4997
    1. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE (2006) Chemotherapy in advanced gastric cancer: a systemic review and meta-analysis based on aggregate data. J Clin Oncol 24: 2903–2909
    1. Woell E, Kühr T, Eisterer W, Gattringer K, Greil R, Zabernigg A, Hilbe W, Thaler J (2006) Oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. Final results of a multicenter phase II trial. J Clin Oncol 24(S18): 195s (abstract 4070)

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir